Form 4: Alkermes EVP R&D Exercises RSUs, Sells Shares for Tax

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, acquired ordinary shares through RSU vesting and subsequently sold a portion for tax obligations.

Summary

• Craig C. Hopkinson, Executive Vice President of Research & Development and Chief Medical Officer of Alkermes plc, reported transactions on February 23, 2026.
• Hopkinson acquired 7,689 ordinary shares through the vesting of a restricted stock unit (RSU) award.
• Following the acquisition, Hopkinson beneficially owned 92,986 ordinary shares.
• Concurrently, Hopkinson disposed of 3,414 ordinary shares at a price of $32.19 per share to cover tax liabilities associated with the RSU vesting.
• After these transactions, Hopkinson's direct beneficial ownership of ordinary shares stands at 89,572.
• The restricted stock unit award vests in four equal annual installments, with the first installment commencing on February 23, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected insider transaction related to executive compensation. The RSU vesting is a positive for the executive, while the tax-related sale is a standard practice, leading to a neutral to slightly positive sentiment.

Positives

• The vesting of restricted stock units indicates a scheduled compensation event, aligning executive incentives with company performance.
• The acquisition of 7,689 ordinary shares through RSU vesting demonstrates the executive's continued equity stake in Alkermes plc.

Negatives

• The disposition of 3,414 ordinary shares, even for tax purposes, reduces the executive's direct beneficial ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this is a standard insider transaction related to executive compensation, common across the pharmaceutical industry for long-term incentive plans. The checkmark for Rule 10b5-1(c) indicates these transactions were pre-planned.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction related to executive compensation, not indicative of a change in company fundamentals or executive confidence.

Next Steps

• Future vesting installments of the restricted stock unit award will occur annually, as the award vests in four equal annual installments commencing on February 23, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives and are often pre-planned under Rule 10b5-1(c), as indicated in the filing. It does not provide new information that would fundamentally alter the investment thesis for Alkermes plc, nor does it suggest a significant change in the executive's confidence in the company. Therefore, a 'hold' recommendation is appropriate based solely on this filing, as it does not present a compelling reason to buy or sell.

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Share Sale, Tax Withholding